Kornimate/medical-research-clean huggingface dataset:
digital measures for clinical trial endpoints in huntington's disease

Conditions: Huntington Disease; Healthy

Summary: mend-hd is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with hd and the meaningfulness of these outcomes for patients with hd and their care partners/support persons. participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life.


Eligibility criteria:
inclusion criteria: * inclusion criteria for participants with adult-onset hd: * age of 25-60 years. * genetically confirmed hd (hd-iss stage 2 or early stage 3) * english speaking. inclusion criteria for control participants: * age of 25-60 years. * english speaking. inclusion criteria for support persons: * self-identified support person or family member of the enrolled participants with hd. * 18 years or older * english speaking. exclusion criteria: * diagnosis of juvenile-onset hd. * history of co-morbid neurological disease or disorders such as stroke, multiple sclerosis, or moderate to severe * traumatic brain injury. * use of an assistive device for ambulation. * montreal cognitive assessment (moca) score of 18 or lower * acute or chronic medical conditions that significantly impact gait or mobility in the opinion of the investigator, e.g. ankle sprain or fracture, or any orthopedic, * cardiovascular or psychiatric disease. * pregnancy * cannot be enrolled into a blinded intervention trial at baseline

Keywords: huntington disease
risk stratifications for patients with palpitations

Conditions: Arrhythmias, Cardiac

Summary: the aim of the study is to early diagnose and early proper mangment of those patients who have palpitations specially of cardiac origin

palpitation : are one of the most common presentations to general practice, and while they are usually benign, they may also have life-threatening significance. palpitations have been estimated to account for 16% of general practice presentations and are the second most common presentation to cardiologists after chest pain.

Eligibility criteria:
inclusion criteria: the present study will be conducted on patients with palpitations "without intently selected certain gender" and had 18 years old or more exclusion criteria: patients refusing study will be excluded.

Keywords: palpitations
safety study of ethinylestradiol/drospirenone in dysmenorrhea

Conditions: Dysmenorrhea

Summary: the purpose of this study is to investigate efficacy of ethinylestradiol for intracyclic bleeding profile in patients with dysmenorrhea and to investigate the long term safety

the "drospirenone 3 mg/ethinylestradiol 20 μg (13 cycles)" group is to be treated by oral administration for 52 weeks, 13 cycles. the "drospirenone 3 mg/ethinylestradiol 30 μg (6 cycles)" group is to be treated by oral administration for 24 weeks, 6 cycles. the trial is sponsored by bayer yakuhin, ltd.

Eligibility criteria:
inclusion criteria: * patients aged 20 years or older at obtaining informed consent * patients having the normal menstrual cycle (25 to 38 days) in the latest two menses before the final enrollment * patients having a total dysmenorrheal score of at least 3 points in twice of the latest menstruation before the final enrollment exclusion criteria: * patients with ovarian chocolate cysts * patients with fibroid needed to be treated * patients with estrogen-dependent tumors and patients with cervical cancer or suspected cervical cancer * patients with undiagnosed abnormal vaginal bleeding * patients with thrombophlebitis, pulmonary embolism, cerebrovascular disease, or coronary artery disease or a history of those diseases * patients aged 35 years or older who smoke at least 15 cigarettes per day * patients with migraine accompanied by prodromata * patients with pulmonary hypertension or valvular heart disease * patients who are regularly taking nutritional products that contain st. john's wort * patients who underwent surgical treatment for endometriosis within 2 months prior to screening * patients who may need to regularly use analgesics for therapeutic objectives other than relief from the pain of dysmenorrhea during this study (occasional use permitted)

Keywords: dysmenorrhea intracyclic bleeding drospirenone (drsp) ethinylestradiol
rubella susceptibility in multiparous women

Conditions: Rubella; Vaccine

Summary: the purpose of this study is to determine the reasons why multiparous women (women who are pregnant and have been pregnant before) might still be susceptible to rubella.

this study is designed to investigate why multiparous women might still be susceptible to rubella. all pregnant women are checked for rubella immunity, and if they are non-immune, there are standard orders in our hospital to administer the rubella vaccine on the post-partum floor prior to discharge home from the hospital. despite this, some multiparous women are found to be susceptible (non-immune), and this study will explore the reasons for this.

Eligibility criteria:
inclusion criteria: * all rubella susceptible women who delivered during the study period.

Keywords: rubella rubella vaccine postpartum immunity
a controlled smoking cessation trial and prospective cohort study of tuberculosis (tb) treatment outcomes

Conditions: Smoking Cessation; Tuberculosis

Summary: the primary focus of this intervention trial is to understand the effect of quitting smoking on tb treatment outcomes. the investigators will compare a cessation strategy based on guidelines recommended by the world health organization (who) and the international union against tuberculosis and lung disease (iutld). this is currently not utilized in tb directly observed therapy (dot) clinics in pakistan. the investigators study will provide comprehensive data towards understanding the effectiveness of these strategies for tb patients who smoke in pakistan, and most importantly, on the effect of quitting smoking on tb treatment outcomes. these findings will guide development of effective smoking cessation strategies in a region with high prevalence of tb and increasing tobacco use.


Eligibility criteria:
inclusion criteria: * males, ≥18 years of age * diagnosed with pulmonary tb * self-reported current smokers, or smoker within 6 months * anticipated to be attending the tb treatment clinic for at least 6 months * be willing to set a quit date within 2 weeks after baseline assessment * agree to participate exclusion criteria: * less than 18 years of age * quit for more than 6 months * extra-pulmonary tb * unable/unwilling to provide written consent
prostate cancer genetic risk evaluation and screening study

Conditions: Prostatic Neoplasm; Prostate Cancer; BRCA2 Mutation; BRCA1 Mutation; ATM Gene Mutation; MMR Mutation; Lynch Syndrome; Genetic Predisposition to Disease

Summary: this study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or black/african ancestry and evaluate the utility of prostate mri as a screening tool. the hypothesis is that this targeted population of men are at elevated risk of developing prostate cancer compared to the general population, and enhanced screening with mri will enable early detection and diagnosis of potentially aggressive prostate cancer, characterization of the penetrance of specific mutations, and potentially identify new genetic risk mutations.

prostate cancer is the most common malignancy and the second leading cause of cancer-related deaths in american men. prostate cancer has substantial inherited predisposition and men harboring specific genetic variants or a positive family history have been associated with an increased risk of developing prostate cancer. men with specific genetic variants, such as pathogenic brca2 mutations, are at particularly greater risk of developing aggressive forms of prostate cancer and thus warrant undergoing careful screening for prostate cancer. however, the penetrance of many mutations in prostate cancer risk genes is unknown, and some men have no identifiable mutations in known risk genes despite a strong family history of prostate cancer. prospectively collected clinical data along with biospecimens from unaffected individuals at high genetic risk for developing prostate cancer will advance the understanding of how specific mutations contribute to the development of prostate cancer and how these prostate cancers might be best detected. the purpose of this study is to prospectively screen men at high risk genetic risk for prostate cancer by prostate exam, psa, and prostate mri to characterize the penetrance and cancer-related outcomes of specific mutations, identify potentially novel genetic risk mutations and/or markers for early detection.

Eligibility criteria:
inclusion criteria: * men 35-74 years old * no known diagnosis of prostate cancer * life expectancy \>10 years * meet cohort a, b, or c criteria * cohort a: documented pathogenic or likely pathogenic germline genetic mutation in a prostate cancer risk gene from a clia-certified laboratory (atm, atr, brca1, brca2, brip1, chek2, epcam, fanca, gen1, hoxb13, mlh1, msh2, msh6, nbn, palb2, pms2, rad51c, rad51d, tp53) * cohort b: a strong family history suggestive of high genetic risk for prostate cancer with negative clinical genetic testing * cohort c: individuals who self-identify as black american or black caribbean with both parents and all four grandparents of black/african ancestry exclusion criteria: * prior diagnosis or treatment of prostate cancer * inability to undergo prostate mri * inability to receive mri contrast agent

Keywords: brca2 brca1 mismatch repair deficiency lynch syndrome hoxb13 family history of prostate cancer
maternal and fetal compatibility in assisted reproductive technology (art)-oocyte donor influences live birth rate

Conditions: Infertility

Summary: has the maternal kir haplotype an impact in pregnancy, miscarriage and live birth rates per embryo transfer in donor oocytes -art by paternal and oocyte donor hla-c?

the combination of maternal kir haplotype and parental, donors hla-c, could predict which couple can benefit for the selection of single embryo transfer (set)/double embryo transfer (det), or donor selection by hla-c in art, in order to increase the live birth rate (lbr)/cycle since hla-c1/c1 donors are predicted to be safer and c2/c2 males or oocyte donors may be mor "dangerous" as identified by epidemiological studies

Eligibility criteria:
inclusion criteria: * bmi between 19 - 27 kg/m2 * blastocyst embryo transfer previous. * normal karyotype, thrombophylic and immunological results. * normal clinical history, viral serology, hormonal analysis (tsh, t4, prolactin, estrogen, progesterone), spermiogram, sperm fish and pelvic ultrasound results. exclusion criteria: * pregnancy women. * psychiatric disorders. * uterus alterations. * polycystic ovary syndrome * genetic and autoimmune diseases. * infectious diseases. * corticoid and immunosuppressant treatments previous.

Keywords: kir hla-c art
the effect of a diabetes action team in patients post infrainguinal bypass surgery with and without diabetes

Conditions: Type 2 Diabetes; Peripheral Vascular Disease

Summary: diabetes is a very common illness. approximately 4% of british columbians have diabetes. however, at least 20% of people admitted to acute care hospitals have diabetes. people with diabetes are at a higher risk for developing complications after surgery including infection and prolonged hospital stay, especially if blood sugars are high. the researchers are testing a diabetes action team to see if their involvement in patient care after surgery improves blood glucose control, duration of stay in hospital, and infection rates.

this trial will randomize subjects with diabetes who plan to undergo elective infrainguinal bypass surgery to receive either standard diabetes care by their admitting physician, or diabetes care under the direction of the diabetes action team post operatively until hospital discharge and post discharge in the community. subjects without diabetes will have their blood glucose levels monitored while in the hospital. the diabetes action team will consist of a nurse coordinator who is a certified diabetes educator (cde) and a team of physicians specialized in the management of diabetes. the study will not increase the length of the hospital stay.

Eligibility criteria:
inclusion criteria: non-diabetes: * fasting blood glucose \< 7.0 mmol/l or a random blood glucose of \< 11.1 mmol/l diabetes: * poorly controlled type 2 diabetes (fasting plasma glucose greater than or equal to 7.0 or random plasma glucose greater than or equal to 10.0 mmol/l) * newly diagnosed type 2 diabetes (fasting plasma glucose greater than or equal to 7.0 mmol/l or random plasma glucose greater than or equal to 11.1 mmol/l) * age \> 30 * english-speaking * agrees to participate in the study and lives in the lower mainland exclusion criteria: * scheduled to undergo surgery other than infrainguinal bypass surgery * under 30 years of age * living outside of lower mainland * cannot speak and understand english

Keywords: type 2 diabetes post-op dysglycemia peripheral vascular disease infrainguinal bypass surgery
comparison of the quality of cpr by lay rescuers with and without feedback devices

Conditions: Cardiac Arrest

Summary: comparison of various methods to improve the quality of cpr

even for paramedics and emergency physicians, the resuscitation of patients with cardiac arrest remains a challenge. previous studies have shown that the cardiac output varies widely even among professional helpers. this is especially due to some very different mean frequencies of cardiac compression wich vary from 60 to 160/min for paramedics. aim of this study is to investigate whether the use of feedback-devices during cardiac-pulmonary resuscitation (cpr) can lead to an improvement of the cardiac output and may improve survival. for this, we examine the impact of different feedback-methods on the frequence-variety on manikin by lay rescuers. overall, we compare three different devices for feedback during cpr. the subjects for this study are lay rescuers who perform a 5 minute chest-compression-only cpr.

Eligibility criteria:
inclusion criteria: * lay rescuers * \>18 years * \<60 years exclusion criteria: * professional rescuers * pregnancy
spanish registry of autoimmune and cholestatic liver diseases (colhai)

Conditions: Hepatitis Autoimmune Disease; Primary Biliary Cholangitis (PBC); Primary Sclerosing Cholangitis (PSC); Cholestatic Genetic Diseases

Summary: the purpose of the registry is to know the status of primary biliary colgantis, autoimmune hepatitis, primary sclerosing cholagitis and genetic cholestatic diseases in spain.


Eligibility criteria:
inclusion criteria: * patients with a confirmed diagnosis for pbc, hai, psc, genetic cholestatic disease exclusion criteria: * refusal to sign the informed consent for the study

Keywords: cholestatic genetic diseases primary sclerosing cholangitis (psc) hepatitis autoimmune disease primary biliary cholangitis (pbc) pfic tipo 1 pfic tipo 2 pfic tipo 3 pfic tipo 4 bric tipo 1 bric tipo 2 alagille syndrome rotor syndrome dubin johnson syndrome genetic disease registry cholestatic diseases
anti-inflammatory nutritional intervention in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: this is a randomized clinical trial, aimed to analyse the effects of a potentially anti-inflammatory nutritional intervention in disease assessment parameters, inflammatory markers, and quality of life of fibromyalgia patients. patients in the intervention group will adopt an anti-inflammatory diet and a diet with a low ingestion of fermentable oligo-, di- and monosaccharides, and polyols (fodmaps), for a 3 months period. group control will adopt a diet based on general recommendations for healthy eating in accordance with the world health organization.

the presence of low grade intestinal inflammation has been reported in fibromyalgia (fm) patients. other studies associate the persistence of symptoms described in fm to possible alterations of the intestinal microbiota composition, i.e. dysbiosis, with consequent existence of small intestinal bacterial overgrowth (sibo). a sample of 100 female patients diagnosed with fm, followed-up at portuguese rheumathology institute in lisbon, will be distributed randomly in two groups. group 1 will adopt an anti-inflammatory diet, which is characterized by the exemption of the intake of potentially inflammatory foods, namely gluten, dairy and ultra-processed foods, over a consecutive period of 3 months. during the first month, a low fodmaps diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months, for a total of 3 months of intervention. group 2 will adopt a diet based on general recommendations for healthy eating in accordance with the world health organization. the ethics committee of the portuguese institute of rheumathology approved this intervention study. the results of this study are expected to determine whether a change in patient nutrition helps to alleviate symptoms, which would optimize medical intervention.

Eligibility criteria:
inclusion criteria: * diagnosis of fm performed by the physician, according to the rome iii criteria of the american college of rheumatology, revised in 2010; * ability to read and sign the informed consent; * stable dose therapy within 4 weeks before study start. exclusion criteria: * patients with pathologies that prevent the follow-up of the given dietary protocol; * patients currently undergoing lactation or pregnancy; * prior or current clinical history of abuse of drug or other substances; * change of therapy during the intervention period; * presence of other inflammatory diseases; * uncontrolled medical conditions (eg. diabetes mellitus, decompensated heart disease, renal failure, neoplastic diseases, liver diseases).

Keywords: antiinflammatory diet low fodmaps diet gluten, casein, sugar and processed-foods free diet nutrition
study of lenalidomide to evaluate safety and efficacy in patients with relapsed or refractory chronic lymphocytic leukemia

Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia

Summary: the purpose of this study is to determine the safety and effectiveness of different dose regimens of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (cll).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years at the time of signing the informed consent form * must be able to adhere to the study visit schedule and other protocol requirements * must have a documented diagnosis of b-cell cll * must be relapsed or refractory to at least 1 regimen for treatment of cll. at least one of the prior treatments must have included a purine analog-based or bendamustine-based regimen * must have an eastern cooperative oncology group (ecog) performance status score of ≤ 2. exclusion criteria: * any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form * active infections requiring systemic antibiotics * systemic treatment for b-cell cll within 28 days of initiation of lenalidomide treatment * alemtuzumab therapy within 120 days of initiating lenalidomide treatment * prior therapy with lenalidomide * history of grade 4 rash due to prior thalidomide treatment * planned autologous or allogeneic bone marrow transplantation * central nervous system (cns) involvement as documented by spinal fluid cytology or imaging. * uncontrolled hyperthyroidism or hypothyroidism * venous thromboembolism within 12 months * ≥ grade 2 neuropathy * uncontrolled autoimmune hemolytic anemia or thrombocytopenia * disease transformation \[i.e. richter's syndrome (lymphomas) or prolymphocytic leukemia\] * participation in any clinical study or having taken any investigational therapy within 28 days prior to initiating lenalidomide therapy
a study to test if trevogrumab or trevogrumab with garetosmab when taken with semaglutide is safe and how well they work in adult patients with obesity for weight loss and fat loss

Conditions: Obesity

Summary: this study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (wegovy®). this study will be done in 3 parts, part a, part b, and part c where different study drugs will be tested. part a of the study is focused on healthy participants. part b and c of the study is focused on participants with obesity. the aim of part a of the study is to see how safe and tolerable the study drug is in healthy participants. the aim of part b and part c of the study is to see how safe and effective the study drug is when combined with wegovy. parts a, b, and c of the study are looking at several other research questions, including: * what side effects may happen from taking the study drug * how much study drug is in the blood at different times * whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

part a healthy volunteers part b and part c (starts after treatment for part a has completed) participants with obesity

Eligibility criteria:
key inclusion criteria part a 1. male or female participants age ≥18 to ≤55 years of age at the time of screening 2. bmi ≥18 and ≤32 kg/m2, at the screening visit part b and part c 3. male or female participants ≥18 to ≤80 years of age at the time of screening 4. bmi ≥30 kg/m2, at the screening visit 5. history of 1 or more self-reported unsuccessful dietary attempts to lose weight key exclusion criteria 1. history of diabetes (type 2 or type 1). history of gestational diabetes is permitted 2. previous bariatric surgery or planned bariatric surgery 3. history of hypertrophic cardiomyopathy 4. abnormal electrocardiogram (ecg) findings at screening that meet cornell voltage criteria for left ventricular hypertrophy 5. any malignancy in the past 5 years prior to screening (except for nonmelanoma skin cancer that has been resected with no evidence of metastatic disease for 3 years prior to screening) 6. history of poorly controlled hypertension, as defined in the protocol 7. have a history of any other condition (such as known drug abuse, alcohol abuse, diagnosed eating disorder, or a severe mental illness) that, in the opinion of the investigator, may preclude the participant from following and completing the protocol 8. have history of use of marijuana/tetrahydrocannabinol (thc) within 90 days prior to visit 1 of enrollment and are unwilling to abstain from marijuana/thc use during the trial 9. has a history of any neuromuscular disorder (eg, multiple sclerosis, myasthenia gravis, myopathy, peripheral neuropathy, etc) note: other protocol-defined inclusion/ exclusion criteria apply

Keywords: obesity without diabetes quality of weight loss fat mass loss lean mass loss